Health Economics›Indolent lymphoma›Relapsed or refractory

Relapsed or refractory

Indolent lymphoma · 31 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 9 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Ofatumumab monotherapy Variant #03	—	R 512 332	28d	~8.1 mo	—	~6	~R 3 073 989 PFS proxy · indirect	4
BVR Variant #01	—	R 142 484	28d	—	—	~5	~R 272 040 indirect	—
Copanlisib and Rituximab Variant #01 Partial	—	R 129 524	28d	~21.5 mo	—	~10	~R 207 238 PFS proxy · indirect	1
Lenalidomide, Dexamethasone, Rituximab Variant #01	—	R 106 870	28d	—	—	~4	~R 116 624 indirect	—
Lenalidomide and Rituximab (R2) Variant #08	—	R 106 523	28d	~39.4 mo	—	~13	~R 141 371 PFS proxy · indirect	1
R-DexaBEAM Variant #01 Partial	—	R 56 818	28d	—	—	~2	~R 113 636 indirect	—
R-FND Variant #01	—	R 38 088	30d	—	—	~4	~R 152 353 indirect	—
Fludarabine and Rituximab (FR) Variant #01	—	R 34 157	28d	—	—	~6	~R 204 943 indirect	—
Bendamustine and Rituximab (BR) Variant #01	—	R 33 874	28d	~34.2 mo	—	~8	~R 270 994 PFS proxy · indirect	4
R-CHOP Variant #08	—	R 26 946	21d	~44.4 mo	—	~6	~R 109 868 PFS proxy · indirect	1
R-INO Variant #01 Partial	—	R 25 905	28d	—	~9.5 mo	~8	~R 207 238 PFS proxy · indirect	1
Vorinostat and Rituximab Variant #01 Partial	—	R 25 905	21d	—	—	~2	~R 51 809 indirect	—
Obinutuzumab monotherapy Variant #06	—	R 23 849	21d	—	—	~4	~R 95 395 indirect	—
Fludarabine monotherapy Variant #05	—	R 13 754	28d	~16.5 mo	~52.9 mo	~6	~R 82 524 PFS proxy · indirect	4
FMP Variant #01	—	R 11 931	21d	—	—	~6	~R 71 587 indirect	—
Bendamustine monotherapy Variant #01	—	R 7 084	—	13.8 mo	—	6	R 42 504 PFS proxy	1
Bortezomib monotherapy Variant #03	—	R 6 762	21d	~30.3 mo	—	~8	~R 54 096 PFS proxy · indirect	5
Lenalidomide monotherapy Variant #01	—	R 2 178	28d	~30.8 mo	—	~13	~R 28 314 PFS proxy · indirect	2
PEP-C Variant #01 Partial	—	R 213	—	—	—	~1	~R 213 indirect	—
Ibritumomab tiuxetan protocol Variant #18 Partial	—	—	8d	~36.5 mo	—	~1	—	1
Rituximab monotherapy Variant #09 Partial	—	—	28d	~17.7 mo	—	~1	—	4
Axicabtagene ciloleucel monotherapy Variant #01 Partial	—	—	—	—	—	~1	—	1
Temsirolimus monotherapy Variant #02 Partial	—	—	28d	~4.8 mo	~17.2 mo	~2	—	3
131Iodine-Tositumomab monotherapy Variant #01 Partial	—	—	—	—	—	~1	—	—
Interferon alfa monotherapy Variant #01 Partial	—	—	7d	—	—	~2	—	—
Duvelisib monotherapy Variant #01 Partial	—	—	28d	~13.3 mo	—	~2	—	1
Copanlisib monotherapy Variant #01 Partial	—	—	28d	—	—	~2	—	—
Vorinostat monotherapy Variant #01 Partial	—	—	28d	~3.1 mo	—	~12	—	1
Inotuzumab ozogamicin monotherapy Variant #01 Partial	—	—	28d	—	~7.7 mo	~5	—	1
Umbralisib monotherapy Variant #01 Partial	—	—	28d	—	—	~2	—	—
Idelalisib monotherapy Variant #01 Partial	—	—	28d	—	—	~2	—	—

31 of 31 regimens shown